Enhanced Composition for Promoting FGF21 Secretion
Legal Citation
Summary of the Inventive Concept
An improved composition for promoting the secretion of fibroblast growth factor 21 (FGF21) by incorporating a prebiotic that selectively stimulates the growth of a specific Bifidobacterium bacterium, leading to enhanced efficacy and safety.
Background and Problem Solved
The original patent disclosed a composition for promoting FGF21 secretion using a Bifidobacterium bacterium. However, the patent did not address the limitation of potential interference from other gut microbiota, which could affect the efficacy of the composition. The new inventive concept addresses this limitation by incorporating a prebiotic that selectively stimulates the growth of the specific Bifidobacterium bacterium, ensuring optimal FGF21 secretion.
Detailed Description of the Inventive Concept
The enhanced composition comprises a Bifidobacterium bacterium, specifically Bifidobacterium breve M-16V (NITE BP-02622), and a prebiotic, such as inulin, at a concentration of 0.5% to 5%. The prebiotic selectively stimulates the growth of the Bifidobacterium bacterium, promoting its colonization and activity in the gut. This results in enhanced FGF21 secretion, which can be beneficial for various health conditions. The composition can be administered orally, and the dosage can be adjusted based on individual needs. A kit for promoting FGF21 secretion can also be provided, comprising the composition and instructions for use.
Novelty and Inventive Step
The new claims introduce the concept of using a prebiotic to selectively stimulate the growth of the Bifidobacterium bacterium, which is not disclosed in the original patent. This innovation provides a significant improvement over the prior art, as it enhances the efficacy and safety of the composition.
Alternative Embodiments and Variations
Alternative prebiotics, such as fructooligosaccharides or galactooligosaccharides, can be used in place of inulin. The composition can also be formulated in various forms, such as capsules, tablets, or powders, to suit different administration routes and patient preferences.
Potential Commercial Applications and Market
The enhanced composition has potential commercial applications in the fields of nutrition, pharmaceuticals, and healthcare. The target market includes individuals seeking to improve their metabolic health, as well as those with specific health conditions, such as diabetes or obesity, where FGF21 secretion is beneficial.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Microbiology, Probiotics, and Nutritional Supplementation, with expertise in bacterial strain manipulation, prebiotic interactions, and metabolic modulation
Person of Ordinary Skill (PHOSITA) Profile
A researcher or practitioner with advanced training in microbiology, capable of understanding bacterial strain characteristics, prebiotic interactions, and metabolic signaling pathways, with knowledge of standard techniques in bacterial cultivation and nutritional supplement formulation
Obviousness Rationale
A person of ordinary skill would recognize that enhancing the growth environment of a specific probiotic strain through targeted prebiotic supplementation represents a predictable and logical extension of the source patent's teachings about Bifidobacterium breve M-16V. The addition of inulin as a selective growth stimulant would be considered a routine optimization strategy for improving bacterial efficacy and metabolic performance. The proposed modifications represent incremental improvements that would be apparent to a skilled practitioner seeking to enhance the original composition's effectiveness.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,579 |
|---|---|
| Title | Composition for promoting the secretion of FGF21 |
| Assignee(s) | Morinaga Milk Industry Co., Ltd. |